Waltham – December, 2010
Parexel White Paper – Review of trends for new drugs
Drug Inovation, approval, market access, and the “new normal”. Emerging FDA review outcome trends for new drugs.
Boston, MA – November 3, 2005
An Introduction to Venture Capital – A Presentation to Tufts University
An overview of the basics of venture capital, and the current venture industry trends and statistics.
Investing in Early Stage Drug Discovery
The focus in biotechnology investing today has shifted in favor of those companies that can generate products. There are two potential products that can be generated in the drug discovery space – drugs themselves, or products and tools used in the drug discovery process (e.g. DNA or protein chips, mass spectrometers, assay reagents, databases and information, platforms, etc.) This article will focus on the former.
Understanding Valuation: A Venture Investor’s Perspective
You have met with several venture firms, responded to countless due diligence inquiries, and a strong lead investor is finally emerging with intent to submit a term sheet. Only one task remains—establishing a valuation.
Venture capital sports a new look
The 2000 meltdown and the consequent shift in investor expectations have undoubtedly changed the face of venture capital. So what are the key characteristics for VC fund success now and in the future? Boston Millennia Partners’ A Dana Callow Jr. takes a look.